Gilead Sciences Inc (MEX:GILD)
MXN 1820 0 (0%) Market Cap: 2.26 Tn Enterprise Value: 2.67 Tn PE Ratio: 109.56 PB Ratio: 6.12 GF Score: 75/100

Gilead Sciences Inc at Robert W Baird Global Healthcare Conference Transcript

Sep 14, 2022 / 01:40PM GMT
Release Date Price: MXN1295.32 (-4.47%)
Brian Peter Skorney
Robert W. Baird & Co. Incorporated, Research Division - Senior Research Analyst

Good morning, everyone. Thank you for joining us our next fireside chat. I'm really pleased to have with me the Chief Commercial Officer of Gilead Sciences, Johanna Mercier. Gilead is a name, I'm sure, everyone is familiar with. It's one of the bellwethers of the sector, a long-standing biotech company with an increasingly diversified portfolio of commercial and development offerings.

So Johanna, thanks so much for joining us today. Really glad to have you here. Maybe to just kind of kick things off, for people who aren't totally familiar with Gilead, you can just give them a very high-level overview of what the company is and is focused on as a biopharma.

Johanna Mercier
Gilead Sciences, Inc. - Chief Commercial Officer

Sure. So it's a softball, I like it. Thanks, Brian. It's great to be here. So thank you. Yes, I think Gilead really has been known as an HIV company. And I think you talked about it a little bit about the diversification. I think

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot